Veru

-$0.14 (-2.99%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Veru and other ETFs, options, and stocks.

About VERU

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT.

CEO
Mitchell Shuster Steiner
Employees
252
Headquarters
Miami, Florida
Founded
1996

VERU Key Statistics

Market cap
364.14M
Price-Earnings ratio
53.17
Dividend yield
—
Average volume
1.21M
High today
$4.90
Low today
$4.52
Open price
$4.77
Volume
718.18K
52 Week high
$24.57
52 Week low
$4.47

VERU News

Simply Wall StJan 21

Veru's five-year total shareholder returns outpace the underlying earnings growth

The last three months have been tough on Veru Inc. (NASDAQ:VERU) shareholders, who have seen the share price decline a rather worrying 36%. But that doesn't und

VERU Earnings

-$0.09
-$0.05
-$0.01
$0.03
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Estimated
— per share
Actual
Available Feb 9, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure